Ann Clin Pharmacol Ther | Volume 1, Issue 1 | Review Article | Open Access
Bothinah K Al-Qahtani1, Samaher AA1, Asma A Alsharif1, Asmaa M Alhamdi1, Samaher S Alkhedaidi1, Sara J Alghamdi1, Batool J Alghamdi1, Hanin A Badr1, Enshrah M Radwan1, Razan A Kalantan1, Rozan A Kalantan1, Raghad A Ghazzawi1, Zahrah E Barnawi1, Wajd W Aqeeli1, Somaya A Khammash1, Renad A Bahadi1, Layan N Alkhayat1, Majdah A Almaghrabi1, Aeshah A Mandili1, Ghada A Bukhari1, Maweyah M Alnejedy1, Shahad N Alsukhayri1, RaghadA Alahmadi1, Kholoud A Alharthi1, Abeer A Kalifih1, Raghad A Alraees1, Muneera M Alelyani1, Shahad M Alzahranim1 and Layla Borham1,2*
1Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Saudi Arabia
2Department of Clinical Pharmacology, Faculty of Medicine, Cairo University, Egypt
*Correspondance to: Layla Ezzt BorhamFulltext PDF
Biosimilars are reliable drugs that are similar to the authorized biological products for treatment of various diseases. They have been produced due to the shortage of biological drugs as a result of the great demand. This article reviews the literature on uses of biosimilar drugs in many different ways.
Biosimilars; Biologics; Inflammatory bowel Syndrome; Infliximab
Al-Qahtani BK, Samaher AA, Alsharif AA, Alhamdi AM, Alkhedaidi SS, Alghamdi1 SJ, et al. Biosimilar Drugs. Ann Clin Pharmacol Ther. 2018; 1(1): 1002.